The service is based on the investment bank BTIG of de Kursziel for Verastem Inc. (NASDAQ:VSTM), which has a note of 3.67 US dollars, from 13.00 US dollars to 20.00 US dollars and the Kaufempfehlung at. Laut InvestingPro-Daten reichen the analyst soul from 7 to 20 US dollars, was a clear warning signal.
Solely for this approval war, the American Arzneimittelbehörde FDA Verastems Zulassungsantrag (New Drug Application, NDA) for the combination of avumetinib and defactinib will be offered. This dealing with the soul of the recidivists KRAS-multiple low-grade serösen Eierstockkrebs (LGSOC) with and without any form of prüft. The Entscheidungsdatum (PDUFA-Date) was celebrated on 30.06.2025.
The BTIG analyst said the drug’s market opportunity was established when the combination was adopted in 2025 as the first FDA-approved treatment option for women with KRASm LGSOC. If there is optimism in the FDA separation, the NDA agreement is one of the first tests conducted by experts, so that knowledge is obtained from one of the expert experts.
In the actual situation of the blessing, the analyst’s prediction is high for the drug combination of 65% to 80%. This new war is a hornet’s nest factor for the Anhebung des Kursziels for the Verastem-Aktien. The calculation of the Kaufempfehlung ensures that the results in the potential of the activity are no longer present. The InvestingPro Analysis said the company has taken on more debt in Bilanz, but that’s a negative EBITDA of $114.48 million.
The previous confidentiality agreement during the FDA is a positive signal for Verastem. This status is of a medical nature, which in treatment means a meaningful treatment in the treatment, diagnosis or prevention can be carried out.
With the push from the FDA on 30.06.2025, Verastems’ position in the oncology market has increased.
InvestPro-Subscriptions are aimed at obtaining more information, which has provided 8 other ProTipps and an additional analysis of Verastem’s financial and market position in Pro Research Report.
More active Entwicklungen zu Verastem:
Analyst Kalpit Patel from B.Riley marked his Kaufempfehlung with a price of 7.00 US dollars, after probably achieving some results for a KRAS G12D-Inhibitor with a Börsengangsantrag from GenFleet Therapeutics that may work. These projects are carried out with Verastem during implementation.
HC Wainwright and Truist Securities are engaged in a Kaufempfehlungen party. Wainwright responds to the current version of RAMP 203 Study, the combination of Avutometinib, Defactinib and Sotorasib with the treatment of KRAS G12C mutiertem non-small lung function study. The user begins his assessment with a confirmation of his knowledge and understanding of KRAS mutations.
Mizuho Securities received an increase of US$9.00 with an “Outperform” rating. The current situation is an umbrella treatment model for Verastems Hauptkrebstherapie Avutometinib plus Defatinib. The analysts now predict an amount of $750 million for 2029.
Verastems Finanzergebnisse im zweiten Quartal übertrafen thanks Meilensteinzahlungen die erwartungen. The factory of Das Unternehmen, which runs 55 million US dollars during a productive Aktienplatzierung einzuwerben. There is a proof of orphan drug status from the FDA for a drug combination with the treatment of Bauchspeicheldrüsenkrebs und veröffentlichte nicht versprechende Zwischenergebnisse from de laufenden RAMP 205-Studie.
This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.